News and Trends 5 Dec 2022
First subject dosed in inflammation phase I study
Innovent Biologics, Inc. and UNION therapeutics A/S have announced that the first Chinese healthy volunteer has been successfully dosed in the phase I study of orismilast, a potential best-in-class PDE4…